Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.

[Back to Overview]  [IACM Homepage]

TitleCannabidiol monotherapy for treatment-resistant schizophrenia
Author(s)Zuardi AW, Hallak JE, Dursun SM, Morais SL, Faria Sanches R, Musty RE, Crippa JA.
Journal, Volume, IssueJ Psychopharmacol 2006;20(5):683-6.
Major outcome(s)CBD monotherapy was not effective in treatment-resistant schizophrenia

Cannabidiol (CBD), one of the major products of the marijuana plant, is devoid of marijuana's typical psychological effects. In contrast, potential antipsychotic efficacy has been suggested based on preclinical and clinical data (Zuardi et al., 2002). In this report, we further investigated the efficacy and safety of CBD monotherapy in three patients with treatment-resistant schizophrenia (TRS). This was an in-patient study. All patients were given placebo for the initial 5 days, and from the 6th to 35th day (inclusive) they received CBD (initial oral dose of 40 mg reaching 1280 mg/day). On day 36th, CBD treatment was discontinued and replaced by placebo for 5 days, which was subsequently switched to olanzapine for over 15 days. Efficacy, tolerability and side effects were assessed. One patient showed mild improvement, but two patients didn't show any improvement during CBD monotherapy. All patients tolerated CBD very well and no side effects were reported. These preliminary data suggest that CBD monotherapy may not be effective for TRS.

Dose(s)40-1280 mg/day
Duration (days)30
Participants3 patients with treatment-resistant schizophrenia
DesignOpen study
Type of publicationMedical journal
Address of author(s)Department of Neuropsychiatry and Medical Psychology, Faculty of Medicine, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil.
Full text

[Back to Overview]  [IACM Homepage]